



IPW

Practitioner's Docket No. NEB-210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kong, Huimin; Vincent, Myriam and Xu, Yan

Application No.: 10/665,633

Group No.: 1635

Filed: September 19, 2003

Examiner: Not yet assigned

For: Helicase Dependent Amplification of Nucleic Acids

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b).

CERTIFICATION UNDER 37 C.F.R. " 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is *mandatory*;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

X deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

X with sufficient postage as first class mail.

37 C.F.R. § 1.10*

G as "Express Mail Post Office to Addressee"

Mailing Label No. _____ (mandatory)

TRANSMISSION

G facsimile transmitted to the Patent and Trademark Office, (703) _____

Signature


Leslie Goldberg

(type or print name of person certifying)

Date: December 8, 2005

* Only the date of filing (' 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under ' 1.8 continues to be taken into account in determining timeliness. See ' 1.703(f). Consider "Express Mail Post Office to Addressee" (' 1.10) or facsimile transmission (' 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

Date: December 8, 2005



Harriet M. Strimpel, D. Phil
Registration No. 37,008
New England Biolabs, Inc.
240 County Road
Ipswich, MA 01938-2723
978-380-7373
Customer No. 28986



Practitioner's Docket No. NEB-210

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Huimin Kong, Myriam Vincent and Yan Xu

Application No.: 10/665,633

Group No.: 1635

Filed: September 19, 2003

Examiner: Not yet assigned

For: Helicase Dependent Amplification of Nucleic Acids

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)
2. Copies of Listed Information Items Accompanying This Statement
3. Identification of Person(s) Making This Information Disclosure Statement

CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

X deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

X with sufficient postage as first class mail.


37 C.F.R. § 1.10*

☐ as "Express Mail Post Office to Addressee"

Mailing Label No. _____ (mandatory)

TRANSMISSION

☐ facsimile transmitted to the Patent and Trademark Office, (703) _____ - _____


Signature

Date: December 8, 2005

Leslie Goldberg

(type or print name of person certifying)

* Only the date of filing (' 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under ' 1.8 continues to be taken into account in determining timeliness. See ' 1.703(f). Consider "Express Mail Post Office to Addressee" (' 1.10) or facsimile transmission (' 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

Section 1. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)

(Insert form(s) PTO/SB/08A [Form 6-2] and/or form(s) PTO/SB/08B [Form 6-2.1].)

Section 2. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.


Refs. BE-BG (note that BF and BG are copies of abstracts that were enclosed in European Search Report)

Section 3. Identification of Person Making This Information Disclosure Statement


The person making this certification is:

- a. the practitioner who signs below on the basis of the information in the practitioner's file.

Date: December 8, 2005



Harriet M. Strimpel, D. Phil
Registration No. 37,008
New England Biolabs, Inc.
240 County Road
Ipswich, MA 01938-2723
978-380-7373
Customer No. 28986



SECTION 2 FORMS PTO/SB/08A and 08B (formerly Form PTO-1449)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kong et al. Atty. Docket: NEB-210-US
Serial No: 10/665,633 Art Group Unit: 1637
Date Filed: September 19, 2003 Examiner Name: Not yet assigned
Invention: Helicase-Dependent Amplification of Nucleic Acids

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Reference Number	Country Code	Document Number	Publication Date	Patentee or Applicant	Class/ Subclass
	BE	EP	European Search Report	11/25/05	EPO	
	BF	JP	07016094 (abstract)	1/20/1995	TOYOBO CO LTD.	C12N 15/09
	BG	JP	05146299 (abstract)	6/15/1993	TOYOBO CO LTD	C12Q 1/68

OTHER DOCUMENTS			
Examiner Initials	Reference Number	Author	Title of Article, Title of Journal, Volume Number, Page Numbers, Date
	DT	Ali et al.	J. Mol. Biol. 293(4):815-830 (1999)

Examiner Signature: _____

Date Considered: _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation *if not* in conformance and not considered. Include copy of this form with next communication to applicant.